Drug Database
AM

amlodipine + celecoxib (Consensi / KIT 302 / KIT302)

✓ Approved

Burke Pharmaceutical · CACNA1C · 小分子

什么是 amlodipine + celecoxib?

amlodipine + celecoxib 是一种小分子,由Burke Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Consensi, KIT 302, KIT302
公司Burke Pharmaceutical
药物类别小分子
分子靶点CACNA1C, PTGS2
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

amlodipine + celecoxib 作用于 2 个分子靶点:

CACNA1Ccalcium voltage-gated channel subunit alpha1 C (NEDHLSS, CACH2)
PTGS2prostaglandin-endoperoxide synthase 2 (hCox-2, PHS-2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

amlodipine + celecoxib 针对 3 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved
Musculoskeletal and connective tissue disordersMusculoskeletal pain✓ Approved
Renal and urinary disordersRenal failurePreclinical

相关研究文献

PubMedPakistan journal of medical sciences2026-11-17

Clinical efficacy of Ruyi Zhenbao Pill combined with supine traction manipulation in the treatment of Cervical Spondylotic Radiculopathy.

Huang Youhan Y, Lv Cunxian C, Xie Zuowan Z, Huang Liangshan L et al.

To explore the clinical efficacy of Ruyi Zhenbao Pill (RZP) combined with supine traction manipulation in the treatment of Cervical Spondylotic Radiculopathy (CSR). This retrospective cohort study was conducted at the Cangnan County Traditional Chinese Medicine Hospital in Zhejiang Province and included medical records of 144 patients with CSR who received treatment between May 2023 to May 2025. Based on treatment modality, and prespecified baseline characteristics, patients were selected to form two comparable groups with a 1:1 group allocation ratio (treated with oral RZP combined with supine traction manipulation) and a control group (treated with oral celecoxib capsules combined with maxillo-occipital traction). Odom's clinical efficacy criteria were used to evaluate the clinical outcome. At three months after treatment completion, the primary outcome, the excellent and good clinical effect rate, was higher in the observation group than in the control group (83.3% vs. 68.1%, P=0.033). In this retrospective cohort, RZP combined with supine traction manipulation was associated with favorable short-term clinical outcomes compared with celecoxib combined with sitting maxillo-occipital traction.

PMID 43041889
阅读全文 →
PubMedFrontiers in medicine2026-11-17

Vanishing bile duct syndrome reports and recorded fatal outcomes in FAERS: a disproportionality analysis.

Yin Yi Y, Zhang Guiju G

Vanishing bile duct syndrome (VBDS) is a rare but life-threatening condition characterized by progressive destruction of intrahepatic bile ducts, often leading to cirrhosis and death. Large-scale pharmacovigilance studies systematically investigating VBDS reports, particularly those with reported fatal outcomes, remain scarce. We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2004 Q1-2025 Q4). VBDS reports were identified using the MedDRA preferred term "Vanishing bile duct syndrome" (Code 10054753). We applied four algorithms-reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM). A positive signal required meeting criteria for all four methods simultaneously. For drugs meeting signal criteria, we further performed a two-dimensional cross-analysis by intersecting drugs with the highest total report counts and those with the highest death counts, to identify drugs appearing in both top-10 rankings. After deduplication, 19,588,161 unique adverse event reports were available, among which 997 reports coded as VBDS were identified. A death outcome was recorded in 193 reports (19.36%); this proportion reflects FAERS reporting patterns and should not be interpreted as VBDS-attributable mortality or a clinical case-fatality estimate. Disproportionality analysis identified 48 drugs meeting all four signal criteria. Notably, only carbamazepine explicitly mentioned VBDS in its FDA label, and merely 18 of the 48 drugs included the broader term "cholestasis". Through cross-analysis of total report counts and reported death counts, six drugs appeared in both top-10 ranking lists: ibuprofen, ciprofloxacin, azithromycin, sulfamethoxazole-trimethoprim, avacopan, and celecoxib. This large-scale pharmacovigilance analysis of FAERS suggests the mention of VBDS among FDA product labels differs across drugs generating post-marketing safety signals, and that this difference warrants further regulatory and clinical evaluation. Six agents (ibuprofen, ciprofloxacin, azithromycin, sulfamethoxazole-trimethoprim, avacopan, celecoxib) appeared in both top-10 ranking lists for total VBDS reports and reported death counts. Because these rankings are based on descriptive absolute FAERS report counts, these agents warrant further clinical and pharmacovigilance evaluation, particularly in patients with pre-existing risk factors for DILI. These findings may support pharmacovigilance surveillance and hypothesis generation, but should be interpreted as reporting associations rather than the evidence of causality.

PMID 43041357
阅读全文 →
PubMedToxicology reports2026-11-16

Refractory circulatory shock following intentional polypharmacy antihypertensive and NSAID overdose: Clinical recovery temporally associated with sequential intravenous lipid emulsion and methylene blue - A case report.

Danial Syed Hussain SH, Honan David Michael DM

Calcium channel blocker (CCB) overdose carries substantial mortality without advanced organ support. Ingestion of a fixed-dose antihypertensive combination with a non-steroidal anti-inflammatory drug (NSAID) is an uncommon polypharmacy toxidrome. The role of intravenous lipid emulsion (ILE) and methylene blue in refractory cases remains poorly defined. A 64-year-old man (135 kg) ingested approximately 300 mg amlodipine, 300 mg perindopril, 75 mg indapamide and 15,000 mg naproxen with ethanol. Despite apparent stability on arrival he deteriorated to 77/47 mmHg, pH 7.20 and lactate 10.5 mmol/L. Seven hours of escalating treatment - noradrenaline (peak 58 mcg/min), vasopressin, calcium and high-dose insulin euglycaemic therapy (HIET) - failed to restore haemodynamic targets. Intralipid 20% was given (total approximately 8.9 mL/kg), followed 35 min later by methylene blue 140 mg (1.0 mg/kg). Lactate fell from 10.5 to 6.1 mmol/L over the subsequent 55 min with the noradrenaline dose unchanged. All vasopressors were stopped within 14 h. HIET was accompanied by concurrent glucose, potassium and phosphate nadirs (1.7, 1.7 and 0.27 mmol/L). KDIGO stage 2 acute kidney injury (peak creatinine 303 µmol/L) required no renal replacement therapy and resolved completely (creatinine 81 µmol/L at 3.5 months). The patient was discharged on day 9. Sequential ILE and methylene blue were temporally associated with rapid metabolic recovery in refractory circulatory shock following polypharmacy antihypertensive overdose. Individual contributions cannot be determined from a single case, and a delayed effect of concurrent HIET cannot be excluded. These agents may represent rescue options when conventional therapy is insufficient.

PMID 43036329
阅读全文 →
PubMedClinical pharmacology and therapeutics2026-11-15

Model-Informed Evaluation of Drug-Drug Interaction Recommendations for Amlodipine and Nirmatrelvir-Ritonavir: A Hypothesis-Generating Analysis.

Ng Tat Ming TM, Chan Bernice Xin Ting BXT, Chen Jiafang J, Tan Angelyn Shu Min ASM et al.

While nirmatrelvir-ritonavir effectively prevents severe COVID-19, its ritonavir component causes significant drug-drug interactions (DDIs). Current guidelines suggest mitigating this interaction by halving the amlodipine dose or moving to every-other-day (EOD) dosing, then resuming the standard regimen 3-5 days post-antiviral treatment. We applied physiologically based pharmacokinetic/pharmacodynamic (PBPK-PD) modeling to evaluate the effects of these recommendations on systolic blood pressure (SBP) control. SARS-CoV-2 inpatients who received nirmatrelvir-ritonavir (October-December 2022) and were exposed to potential DDIs were identified. An amlodipine PBPK-PD model incorporating the diurnal variation of SBP was developed. The model was validated using amlodipine PK studies, including in DDI scenarios, while the PD model was validated against SBP data collected during amlodipine treatment. Simulations were performed in representative virtual populations, comprising various amlodipine doses and regimens, during and after nirmatrelvir-ritonavir therapy. 362/1729 (20.9%) drugs from 166/217 (76.5%) patients were identified to have potential DDIs implicating nirmatrelvir-ritonavir. Amlodipine was a common interacting drug (64/362, 17.7%) and often prescribed without dose adjustment (63%). Our simulations supported that continuing amlodipine during therapy may lead to SBP ≤100 mmHg at daily doses of ≥5 mg, while discontinuation may lead to SBP >130-150 mmHg. Halving the amlodipine dose during nirmatrelvir-ritonavir treatment could provide more stable SBP control than EOD dosing. Resuming usual doses 3 days after nirmatrelvir-ritonavir could be more important in those receiving 7.5 and 10 mg of amlodipine. DDIs between nirmatrelvir-ritonavir and amlodipine were common. Our simulations evaluated current dose adjustment recommendations for amlodipine with mechanistic quantitative reasoning.

PMID 43033131
阅读全文 →
PubMedThe Lancet. Global health2026-11-14

Community health worker-led hypertension management with independent prescribing in rural Lesotho: a cluster-randomised non-inferiority trial.

Gerber Felix F, Sanchez-Samaniego Giuliana G, Gupta Ravi R, Lejone Thabo Ishmael TI et al.

Hypertension is the leading global risk factor for premature mortality, yet treatment coverage and control remain poor, particularly in low-income and middle-income countries. Whether community health workers can manage hypertension, including independent prescribing and titrating of antihypertensive therapy, remains unknown. We aimed to assess whether hypertension care led by community health workers with independent prescribing was non-inferior to usual facility-based care for maintaining blood pressure control among adults with treated, controlled hypertension. We conducted a pragmatic, cluster-randomised, open-label, non-inferiority trial in 103 villages in rural Lesotho. Adults with treated, controlled hypertension (<140/90 mm Hg) were eligible. Villages were randomly assigned 1:1, stratified by district and access to health facility, by an independent statistician using a computer-generated sequence to hypertension care led by community health workers, including independent prescribing and titrating of antihypertensive therapy (amlodipine/hydrochlorothiazide combination pills at doses of 5 mg amlodipine and 12·5 mg hydrochlorothiazide or 10 mg amlodipine and 25 mg hydrochlorothiazide) with clinical decision support, or to usual nurse-led, facility-based care. The primary endpoint was blood pressure control at 12 months among all randomised participants except individuals who became pregnant during follow-up, with a non-inferiority margin of -10 percentage points absolute risk difference. The study has been completed and is registered with ClinicalTrials.gov (NCT05684055). Between Sept 8, 2023, and May 31, 2024, we enrolled 807 participants (417 in 51 control villages, 390 in 50 intervention villages; two empty clusters; mean age 64·4 years [SD 14·3]; 82% female). At 12 months, blood pressure was controlled in 300 (78%) of 386 participants in the intervention group and 303 (74%) of 412 in the control group (adjusted odds ratio 1·29, 95% CI 0·93-1·80); non-inferiority was met. The adjusted absolute risk difference was 5·1% (95% CI -0·9 to 11·2). Serious adverse events (deaths and hospitalisations) were similar in the two groups, with no excess events attributed to the intervention. These findings support community-based hypertension care with task-sharing to trained community health workers as a promising approach to maintaining blood pressure control, especially in settings with limited access to physician-led and nurse-led hypertension care. Swiss Agency for Development and Cooperation, World Diabetes Foundation, and Swiss National Science Foundation.

PMID 43025432
阅读全文 →
PubMedNanomaterials (Basel, Switzerland)2026-11-14

Vancomycin-Stabilized Copper Nanoclusters: Isolation by Solid-Phase Extraction and Application in Chiral Capillary Electrophoresis.

Kolobova Ekaterina A EA, Demenshin Andrei I AI, Zimarina Yulia P YP, Solovyeva Elena V EV

Utilizing state-of-the-art nanomaterials for chiral discrimination is an emerging area of analytical research. Herein, we explored for the first time, metal nanoclusters as a chiral selector in capillary electrophoresis. Vancomycin-stabilized copper nanoclusters (CuVanc NCs) were intentionally synthesized, purified and characterized by UV-Vis and fluorescence spectroscopy, transmission electron microscopy, dynamic light scattering, and X-ray photoelectron spectroscopy. The 5-step sequential protocol of solid-phase extraction was designed to isolate CuVanc NCs from the as-synthesized solution before electrophoretic experiments. The recovery was found to be over 90%. The purified CuVanc NCs were utilized as a chiral discriminator for enantioselective recognition of model drugs. The effects of key parameters, including the pH value of the running buffer and concentration of CuVanc NCs, were assessed. Chiral separation was successfully achieved for both positively and negatively charged analytes, with the better enantioselectivity observed for amlodipine (α = 1.017) and acenocoumarol (α = 1.015), respectively. The separation behavior was strongly influenced by the background electrolyte pH and nanocluster concentration, balancing electrostatic interactions and electrophoretic mobility. Overall, the study highlights a high potential of metal nanoclusters as effective chiral selectors in capillary electrophoresis, opening up new opportunities for chiral analysis and pharmaceutical quality control.

PMID 43029382
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多amlodipine + celecoxib